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ABSTRACT 
Background: The recognized spectrum of impulse control disorders in Parkinson’s 
disease (PD) includes pathologic gambling, hypersexuality, compulsive buying, and 
binge eating, and is commonly related to exposure to dopamine agonist medications. 
Sweet craving in the general population is a phenomenon that is closely linked to 
several factors, including poor impulse control.  Craving for sweets, though recognized 
to occur in PD, has not previously been studied. 
 
Methods: First, patients with idiopathic PD and normal controls who reported craving 
sweets completed craving questionnaires (CQ), taste threshold testing, assessment of 
mood symptoms and olfactory testing. CQ scores were correlated with these results and 
other demographic information. A pathologic craving score was identified as the 75th 
percentile of the mean CQ score for all PD patients. Second, patients with PD and 
controls completed a series of questionnaires addressing the presence of a variety of 
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impulse control disorders and sweet craving to determine the prevalence of sweet 
craving in PD and disease and medication-related factors that are associated with each. 
 
Results: Craving for sweets is present in about 5.5% of patients with idiopathic PD. 
Similar to the determinants of other ICDs, determinants of sweet craving include female 
gender (p=0.0001), decreased olfactory function (t-test: p=0.0001; fisher’s exact method: 
comparing QSIT scores of 0 and 2 (p=0.0179), 0 and 3 (p=0.0182)), self-reported current or 
past history of depression (p=0.048) and obsessive-compulsive traits (p=0.044), higher 
Hoehn & Yahr staging (p=0.0001; fisher’s exact method: no significance), younger onset 
of disease (p=0.015), and longer duration of disease (p=0.003). 
 
Conclusions: Craving for sweets in PD is similar in its phenomenology to other 
recognized ICDs in this population of patients. Though the potential implications of this 
behavior may be less hazardous than those of other pathologic behaviors, it broadens 
the spectrum of ICDs that should be recognized in PD and discussed with patients.  
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INTRODUCTION 
Parkinson’s disease (PD) is a neurological disorder that is characterized by the 
slow degeneration of dopamine-producing nerve cells in the brain. Dopamine is a 
neurotransmitter that helps to control movement. As a result of its loss, patients suffer 
from motor disability including tremor, stiffness, slowness of movement and loss of 
balance (Davie, 2008). Although there is no cure for PD, different treatment options aim 
to alleviate some of the motor and non-motor symptoms. Dopaminergic therapies are 
most common, including levodopa and dopamine agonists (DAs). Levodopa, a form of 
dopamine, can be taken orally and crosses the blood-brain barrier where it is converted 
to dopamine and exerts central nervous system effects. DAs stimulate dopamine 
receptors, thereby mimicking the effects of levodopa. Side effects of DAs include 
hypotension, nausea, disorientation, aggravation of emotional states like anxiety, 
obsessionality-compulsivity and depression, hallucinations, dyskinesia and impulse 
control disorders (Perez-Lloret 2010). 
Impulse control disorders (ICDs) in Parkinson’s disease (PD) are thought to 
occur in approximately 5.9 to 13.6% of patients and are closely linked to dopamine 
agonist exposure (Kenangil 2010, Weintraub 2010). Risk of ICDs in PD also vary 
according to age, gender, marital status, tobacco use, age at PD onset, and family history 
of gambling or alcoholism (Weintraub 2010, Voon 2007). Personal history of alcohol use, 
impulsive traits, and novelty seeking traits are also associated with greater risk of ICDs 
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(Voon 2007). Recognized ICDs include pathologic gambling, compulsive buying, binge 
eating, hypersexuality and other behaviors, such as punding, hobbyism, and dopamine 
dysregulation syndrome (Weintraub 2010). The pathophysiology of ICDs in PD is likely 
related to dopamine receptor stimulation in the reward systems of the nucleus 
accumbens and dorsomedial frontal lobes (Okai 2011, Muresano 2012, Cardinal 2001).   
ICDs can have a negative impact on a patient’s quality of life. Pathologic 
gambling and compulsive buying can have serious financial implications, whereas binge 
eating and hypersexuality can lead to major health risks. All of these conditions cause 
great personal stress on the patient and his or her family, and thus should be seriously 
considered, assessed and discussed throughout the course of treatment (Vilas 2012).  
 
Specific Aims  
Craving for sweets is a recognized but currently un-studied phenomenon in PD. 
The purpose of this study is to determine the prevalence and correlates of sweet craving 
and other impulse control disorders in Parkinson’s disease and to investigate whether 
sweet craving represents a form of ICD in PD. Our specific aims are to:  
1. describe the phenomenology of sweet craving in PD, 
2. study factors that might influence or correlate with sweet craving in PD and 
controls such as olfactory loss, taste perception, underlying affective disorder 
and various PD-related features (e.g., PD duration, PD severity, and PD 
medications), 
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3. determine the prevalence of sweet craving in a PD cohort, and 
4. identify the correlates of sweet craving and other ICDs in the same 
population of patients 
 
We hypothesize that sweet craving in PD represents a form of ICD. Shedding 
light on the phenomenon of sweet craving in PD will help practitioners recognize this 
occurrence, and counsel or manage patients accordingly.  
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BACKGROUND 
PD and Treatment 
Parkinson’s disease is a neurodegenerative disorder characterized by loss of the 
dopamine-producing neurons in the substantia nigra, leading to dopamine deficiency in 
the central nervous system. In a healthy patient, dopamine from the substantia nigra 
influences basal ganglia pathways to control complex movements. In a patient with 
Parkinson’s disease, the lack of dopamine signaling and other degenerative changes 
cause a variety of motor and non-motor symptoms to occur (Davie, 2008). 
Motor deficits take the form of tremor, bradykinesia, rigidity of the neck and 
limbs, and postural instability. In addition, patients may display reduced arm swing on 
the affected side of their body, shuffling or freezing gait, micrographia, and loss of facial 
expressions. Non-motor symptoms of PD include low voice volumes, mood disorders 
(depression or anxiety), constipation, hallucinations, cognitive impairment, orthostatic 
hypotension, loss of sense of smell, pain, drooling and sleep disturbances (Davie, 2008). 
While there is no cure for Parkinson’s disease, treatment options aim to alleviate 
the symptoms of PD. Because many of these symptoms are caused by a lack of 
dopamine, it is beneficial to treat patients with drugs that can replace the dopamine, 
block its degradation or stimulate dopamine receptors. Levodopa (L-dopa) is an oral 
medication that crosses the blood-brain barrier and is converted to dopamine. The 
medication can be administered in several formulations, and side effects include nausea, 
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low blood pressure, somnolence, and hallucinations.  Long-term complications of L-
dopa therapy include dyskinesias. Drugs that inhibit breakdown of dopamine can also 
enhance the effects of dopamine replacement therapy by allowing dopamine to be 
maintained in the brain for a longer period before degradation.  Examples include 
monoamine oxidase (MAO) inhibitors and catechol-o-methyl transferase (COMT) 
inhibitors.  By contrast, dopamine agonist (DA) drugs bind to dopamine receptors, 
mimicking the effects of dopamine. Ropinirole, pramipexole, rotigotine, and 
apomorphine are all examples of DAs. Side effects of DAs are low blood pressure, 
hallucinations, nausea, hypersomnolence and impulse control disorders (Davie, 2008). 
 
Impulse Controls Disorders 
Impulse control disorders (ICDs) are behavioral disorders in which one’s ability 
to resist temptation is limited, even if that temptation can lead to the harm of oneself or 
others (Vilas 2012). The spectrum of ICDs includes pathological gambling, binge eating, 
pyromania, compulsive shopping, kleptomania, intermittent explosive disorder, 
compulsive computer use, hypersexuality, and compulsive skin picking (Muresano 
2012). Like substance abuse disorders, ICDs are thought to initially provide relief to a 
certain tension. However, over time, the behavior becomes habitual despite the fact that 
the patient stops feeling the same relief or pleasure from committing the act (Muresano 
2012).  
6 
 
ICDs are thought to occur in Parkinson’s disease patients as a result of 
dopaminergic therapy. Out of the entire spectrum of ICDs, studies have identified 
compulsive gambling, compulsive shopping, hypersexuality, and binge eating in PD, 
along with disorders like hobbyism, punding and dopamine dysregulation syndrome 
(DDS) (Kim 2012, Leeman 2011, Weintraub 2010, Weintraub 2012). Understanding the 
presence of ICDs amongst Parkinson’s disease patients is important because ICDs can 
have serious financial, medical and psychological consequences for the patient.  
Unfortunately, the presence of ICDs is not always recognized or acknowledged by 
affected patients or family members. It has been speculated that this might be due to 
embarrassment, or perhaps because patients and their families do not identify that the 
behavior might be linked to their treatment for PD (Bastiaens 2013, Weintraub 2012). 
Early recognition of the development of an ICD in PD is important in order to prevent 
the behaviors from becoming habitual (Vilas 2012).   
 The estimated prevalence of ICDs amongst Parkinson’s disease patients ranges 
from 5.9% (Kenangil 2010) to 13.6% (Weintraub 2010), with one prospective study 
showing that 39.1% of PD patients developed an ICD over time (Bastiaens 2013). The 
largest and most cited study evaluating the prevalence of ICDs in PD is the DOMINION 
cross-sectional study (N=3090) from North America. This study reported an overall 
prevalence of 13.6%, with 3.9% of patients experiencing 2 or more ICDs. They found that 
5% of patients experienced gambling, 3.5% experienced compulsive sexual behavior, 
5.7% compulsive buying and 4.3% binge-eating disorder (Weintraub 2010). In order to 
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obtain this data, the DOMINION study designed an interview that used formal 
diagnostic criteria to diagnose these four types of ICDs. One major strength of this study 
was the strong effort taken to avoid selection bias. Every third patient with a diagnosis 
of idiopathic PD that fell into a specified age range and a defined pattern for treatment 
was interviewed. The interviewer had no previous knowledge as to whether a patient 
had a current ICD or not. This selection plan diminished the chances of a patient being 
selected for the study based on the investigator’s knowledge of whether or not an ICD 
was present. A possible weakness of this study was that the interview was limited to 
only inquiring about gambling, hypersexuality, computer use and binge eating. As a 
result, the overall prevalence of ICDs in PD patients might be underestimated.  
 Kenangil et al (2010) examined 554 PD patients in a prospective study over a 3 
year period at an outpatient clinic in Turkey. From this group, 33 patients were found to 
have ICDs (5.9%). 65 PD patients without ICDs were selected as controls and matched to 
the PD/ICD group by disease duration, gender and age and then these groups were 
compared over PD-related factors. There were no significant differences between these 
groups in severity of PD, L-dopa equivalent doses of DAs, or presence of L-dopa 
induced motor complications.  5.9% is a lower prevalence than what has been found in 
Western studies. A possible explanation for this is that there are no casinos in Turkey, 
which means that the incidence rate of compulsive gambling might be lower due to 
location. The study did not use a standardized screening questionnaire for ICDs, which 
also may have contributed to a lower prevalence.  
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 In 2013, Bastiaens et al published a 4 year prospective study of ICDs in PD 
patients. They examined a cohort of outpatients with PD and no previous ICDs (N=164), 
46 of whom were either given DA treatment for the first time or were continuing their 
DA treatment. 18 patients out of the 46 on DAs developed new-onset ICDs (39.1%). 
Diagnosis of an ICD was made by a physician after interviewing the patient and those 
that observe the patient’s behavior. A behavior was considered to be an ICD if it caused 
disruption to work or social interactions or if it had psychological penalties for the 
patient. The most common ICD was compulsive eating, affecting 16 out 18 patients. 6 
out of 18 experienced hypersexuality, 5 subjects experienced compulsive shopping and 1 
patient experienced compulsive gambling. Affected patients typically developed an ICD 
3.0 to 114.0 months after they started taking a dopamine agonist. This study is 
significant in that it examined the prevalence of ICDs in PD in a prospective manner, 
with the majority of past studies being cross-sectional or respective by design. Another 
strength of the study is that the interview was not limited to certain ICDs – they 
inquired about all repetitive behaviors and asked follow-up questions to define the 
scope and pattern of such behavior. Limitations to the study were its relatively small 
sample size and the use of clinical diagnosis instead of the formal diagnostic criteria for 
ICD diagnosis, which may have resulted in an overestimation of the prevalence of ICDs 
(Bastiaens 2013).  
 
 
9 
 
Risk Factors for ICDs in PD 
 Studies have found that PD patients with ICDs are more likely to be unmarried 
(Leeman 2011, Weintraub 2010), have more formal education (Weintraub 2010) and have 
a past or current history of cigarette smoking and a personal or familial history of 
gambling (Bastiaens 2013, Weintraub 2010). They are likely to be younger (Kim 2012, 
Voon 2007 Weintraub 2010) with a younger onset and longer duration of PD (Kim 2012), 
which is possibly explained by the fact that younger patients are often first treated with 
DAs because of the risk of developing complications associated with levodopa treatment 
such as dyskinesia (Bastiaens 2013) and DA treatment, especially in high doses, has been 
suggested to increase the likelihood of ICD development (Rana 2013).  In the 
DOMINION study, however, this “age effect” was tested and remained significant after 
controlling for DA exposure (Weintraub 2010). Possible implications for these findings 
are that younger patients are more physically fit and are culturally different than older 
patients, which can affect the type of compulsive behaviors that they adopt. For 
example, compulsive computer use might be a behavior that becomes more common in 
future generations. Compulsive gambling and hypersexuality have been associated with 
the male gender (Vilas 2012, Weintraub 2010), whereas compulsive buying and binge-
eating have been associated with the female gender (Weintraub 2010). ICDs have also 
been associated with obsessionality-compulsivity, anxiety and depression (Voon and 
Stacy 2011, Leeman 2011).  
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Dopamine Agonists and ICDs 
 Based on current literature, the most consistent predictor for the development of 
ICDs in PD patients is treatment with DAs (Bastiaens 2013, Ondo 2008, Weintraub 2010). 
This linkage is consistent across the DA class, with similar frequencies of ICDs occurring 
with pramipexole and ropinirole treatment (Vilas 2012, Weintraub 2010). The 
DOMINON study found that the odds of having an individual ICD were 2 to 3.3 times 
higher in patients treated with DAs compared to patients not treated with DAs 
(Weintraub 2010). The study also found that L-dopa therapy is associated with an 
increased likelihood of ICDs independently of DA treatment, but that the odds of having 
an ICD were higher in patients treated with a DA without L-dopa treatment, than in 
patients treated only with L-dopa (OR, 2.60; 95% CI, 1.97-3.43;  P<0.001) (Weintraub 
2010). Patients who are taking a combined therapy of both DA and L-dopa were found 
to have increased odds of developing an ICD by close to 50% when compared with 
patients only on DA treatment (OR, 1.42; 95% CI, 1.02-1.98; P<0.001) (Weintraub 2010). 
The conclusion that DA usage is the probable cause of a development of ICDs in 
PD patients is strengthened by the Weintraub study (2013) that compared de novo 
untreated PD patients with healthy controls to determine if PD itself somehow causes an 
increased risk for ICDs, instead of that risk coming from treatment only. The study 
recruited 168 untreated PD patients of recent diagnosis and 143 healthy controls. They 
looked for current ICDs and related behavioral symptoms based on the Questionnaire 
for Impulsive-Compulsive Disorders in Parkinson’s disease (QUIP) Short Form. This 
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study found no significant difference in prevalence of ICDs between untreated PD 
patients and healthy controls. The authors suggest instead that the greater incidence of 
ICDs amongst treated PD patients is likely caused by dopamine replacement or other 
therapies, in combination with risk factors like familial or personal history of ICDs and 
other demographic variables (Weintraub 2013).  However, this study was cross-sectional 
in nature, and did not follow untreated PD patients over a length of time to determine if 
separate disease related factors could also contribute to the presence of ICDs.  
 There are multiple theories that attempt to explain why dopamine agonist 
treatment seems to be more highly associated with ICDs in PD than L-dopa treatment. 
One theory is referred to as the “overdosing” hypothesis. Degeneration of dopamine 
producing neurons in PD is thought to initially occur in the ventrolateral and caudal 
areas of the substantia nigra pars compacta, which limits dopamine projections to the 
dorsal striatum and causes impaired motoric behaviors (Leeman 2011). By contrast, the 
ventral striatum, which projects to the brain’s reward system, is unaffected in the 
beginning stages of PD (Voon and Hallet 2011, Leeman 2011). The overdosing theory 
hypothesizes that dopamine replacement therapy that is titrated to treat motor 
symptoms, and hence dorsal striatal deficits may cause an overdosing of the intact 
ventral striatal cognitive and limbic pathways. This results in increased stimulation to 
areas of the brain that have been associated with both behavioral addictions and 
substance abuse disorders (Voon and Hallet 2011). 
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In opposition to the overdosing hypothesis, which assumes that the ventral 
striatal pathways of the brain are intact in PD patients with ICDs, some studies have 
hypothesized that ICDs are a result of disruption or dysfunction of this area of the brain. 
In 2012, Bentivoglio et al published a study that compared 17 Parkinson’s disease 
patients with ICDs to 17 Parkinson’s disease patients without ICDs. They matched the 
patients according to disease duration, age, education, scores on UPDRS-part III and 
overall cognitive status, with the goal of discovering variables that might lead to the 
development of an impulse control disorder. The study could not find any significant 
differences between the two groups; however, they did notice trends of lower scores in 
the PD ICD group on tests that detected dysfunction of ventral fronto-striatal pathways 
by measuring inhibition of automatic responses. The study noted that this disruption 
might decrease a patient’s ability to resist the immediate reward, even if that means that 
they suffer a long term detriment (Bentivoglio 2012).   
 The increased frequency of ICDs with dopamine agonist treatment versus L-
dopa treatment might be explained by examining dopamine-receptor binding 
preferences of each drug (Weintraub 2010). Second generation non-ergot dopamine 
agonists like pramipexole and ropinirole exhibit relative selectivity for D3 receptors over 
D2 and D1 receptors (Levant 1999). D3 receptors, which are abundant in the ventral 
striatum (Gurevich 1999), may mediate reward, while D2 and D1 receptors, which are 
abundant in the dorsal striatum (Gurevich 1999), may mediate movement. Therefore, 
drugs that preferentially act on D3 receptors, like dopamine agonists, may lead to an 
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overstimulation of the ventral striatum. L-dopa, on the other hand, demonstrates 
relative selectivity for D2 and D1 receptors over D3 (Gerlach 2003). The DOMINION 
study postulates that these binding preferences explain why DAs are more strongly 
associated with ICDs (Weintraub 2010).  
 
Craving for Sweets 
Craving for sweets is a phenomenon that occurs in the general population. 
People tend to have specific types of sweets that they crave over others – for example, 
hard candy, chocolate or sugary beverages. Past studies have found that in the general 
population, women tend to crave sweets over savory foods, whereas men tend to crave 
savory foods over sweets (Zellner 1999).  
In the normal aging population, there is a decrease in the size of the olfactory 
bulb and other cellular structures related to smell perception whereas no diminution of 
taste receptor density is found (Kaneda 2000). In support of this, in 2010, Deeb et al 
found that olfactory deficits that occur in PD were not associated with taste deficits. It is 
well recognized that taste and smell senses are closely linked, and that most taste 
perceptions rely to some degree on olfactory sensations (Mojet 2005). It has been 
suggested that patients with PD have enhanced taste perception, perhaps to compensate 
for olfactory deficits (Sienkiewicz-Jarosz 2005). However, in opposition to this theory, 
Shah et al found significant taste impairment in PD patients when compared with 
healthy controls (Shah 2009). This finding was repeated in 2011 when Kashihara et al 
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found that both smell and taste impairment occurred in a higher frequency in PD 
patients than in controls (p<0.0001 and p=0.0142). In the general population, females 
were more likely to experience carbohydrate cravings than men (Zellner 1999), and these 
sweet cravings were commonly associated with “negative” mood states like depression 
(Jeffery 2009). Past studies have reported the prevalence of depression in PD patients to 
be as great as 40% (Prado 2005). A report of 7 PD patients experiencing binge eating 
after beginning a dopamine agonist also described the presence of food and sweet 
cravings in 3 of the subjects, with subsequent resolution of symptoms after 
discontinuation of the offending agent (Nirenberg and Waters 2006). However, craving 
was not formally assessed. 
Although craving for sweets in Parkinson’s disease patients is a relatively un-
studied phenomenon in comparison to other compulsive behaviors, it has been 
acknowledged in previous literature. In 2009, Wolz et al mailed questionnaires to 498 PD 
patients and their healthy partners to determine if consumption of chocolate and other 
types of sweets was significantly higher in PD patients. 274 of the PD questionnaires and 
234 of the control questionnaires were eligible for analysis. The study found that weekly 
chocolate consumption was significantly higher in PD patients when compared to 
healthy controls (p<0.0001). This association remained true despite possible confounding 
factors such as age and gender. Although weekly consumption of non-chocolate sweets 
was also higher in the PD group than in healthy controls, the study did not find 
significance in this disparity (p=0.45) (Wolz 2009). Limitations to the study were the use 
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of an at-home anonymous self-questionnaire, which removed the physician’s ability to 
analyze the validity of certain factors like depression and body weight, and the use of 
spouses as healthy controls, which is considered to be a weak comparison group for 
eating studies (Wolz 2009).  
Based on our experience of PD patients reporting a new craving for sweets and 
on our review of the above data, we sought to explore the relatively un-reviewed 
relationship between sweet craving and PD. Our study aimed to identify the prevalence 
and correlates of sweet craving in PD in order to establish whether sweet cravings 
represent another form of ICD in PD.  
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METHODS 
Our examination of sweet cravings in PD patients was completed in two parts, with the 
following objectives: 
 Part One: To explore possible determinants of sweet craving in PD, 
including non-PD factors. 
 Part Two: To examine the prevalence of sweet-craving in PD, PD-related 
factors that might have influenced the craving , and sweet craving in the 
broader context of ICDs . 
Part One 
 Patients with probable idiopathic PD (Gelb 1999) seen at the Parkinson’s Disease 
Center and Movement Disorders Clinic (PDCMDC) of Baylor College of Medicine were 
asked to participate in a study aimed at identifying factors that might influence sweet 
craving in PD. Control subjects were comprised of unaffected spouses or caregivers of 
PD patients.  Subjects were excluded from participation if they were unable or unwilling 
to complete all assessments by themselves or with the assistance of a caregiver or study 
coordinator. All subjects completed the following assessments: 
1. Quick Smell Identification Test (Q-SIT, Sensonics, Inc.): This is a short scratch-
and-sniff test of three odors based on the University of Pennsylvania Smell 
Identification Test (Doty et al 1984).  
2. Taste threshold testing:  Various concentrations of solutions (Table 1) 
representing the four taste sensations [sweet (sucrose), salty (sodium chloride), 
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bitter (quinine hydrochloride), sour (citric acid)] and plain water were soaked 
onto circles of filter paper and dried. Subjects placed each filter disc (in a blinded 
fashion in a predetermined random order) on their tongue for at 5-10 seconds 
and were asked to identify the taste (Mueller et al, 2003). The taste threshold is 
identified as the lowest concentration at which the subject could correctly 
identify the flavor, with a lower threshold indicating more sensitive taste.  
3. Modified Symptom Checklist-90-R (SCL-90-R): The original SCL-90-R is a self-
report measure addressing nine primary psychiatric dimensions in 90 questions. 
Subjects answered questions corresponding to the anxiety, depression, and 
obsessive-compulsive subscales only (total questions = 33, Derogatis et al, 1976). 
4. Sweet Food Frequency Questionnaire (FFQ): Modified from the Arizona FFQ 
(Martinez et al, 1999). Subjects quantified the average frequency of intake of 
sweet foods before and after development of PD symptoms.  
5. Sweet Craving Questionnaire (CQ): Modified from the Alcohol Craving 
Questionnaire, Short Form, Revised (ACQ-SF-R) (Singleton et al, 2003). If 
subjects stated they craved sweets, they answered 12 questions about their 
craving based on the food item they reported wanting or eating the most. CQs 
were scored according to published guidelines for the ACQ (Singleton et al, 
1994).  
 Those with a CQ score >75th percentile within their group (PD patients or 
controls) were considered “problem cravers”. Differences in continuous variables 
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between cravers and non-cravers were tested by the two-tailed Student’s t-test. For Q-
SIT and Hoehn & Yahr scores, the specific scoring groups were compared using Fisher’s 
exact method and the mean scores were compared using a student’s t-test.  Taste 
thresholds were also compared using Fisher’s exact method. In the patients identified as 
problem cravers, correlations between the CQ score and various factors were performed.  
 PD patients were compared with controls using the same methods. Levodopa 
equivalent doses were calculated based on Tomlinson 2010.  
 
Part Two 
 We asked a second group of patients with probable PD (Gelb 1999) and controls 
(comprised of spouses of PD patients and non-PD patients seen in our clinic) to 
complete a series of self-rated questionnaires derived from the literature addressing 
various possible impulse control disorders: 
1. South Oaks Gambling Screen (SOGS; Lesieur and Blume, 1987) 
2. Yale-Brown Obsessive Compulsive Screen – Shopping Version (YBOCS-SV; 
Koran et al, 2003)  
3. Yale-Brown Obsessive Compulsive Screen – Computer Use Version (YBOCS-
CUV; modified from the YBOCS-SV) 
4. Yale-Brown Obsessive Compulsive Screen – Binge Eating (YBOCS-BE; McElroy, 
2003)  
5. Sexual Compulsivity Scale (SCS; Kalichman and Rompa, 2001)  
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6. CQ  
 We obtained the following data for each PD patient: age, duration of PD, current 
or past history of psychiatric problems, basic demographic information, PD medications, 
and UPDRS Part III. In control patients, we made note of their age, and current or past 
history of psychiatric problems. All subjects completed all questionnaires. In case of 
incomplete questionnaires, subjects were contacted to score the missing items.  
 Mean scores on the various questionnaires were compared between controls and 
PD patients, controls and PD patients taking dopamine agonists and controls and PD 
patients not taking dopamine agonists, using two-tailed z-hypothesis testing. Scores on 
each scale were correlated with various factors by calculating Pearson’s correlation 
coefficients. PD patients with a compulsive behavior (ICD and/or sweet craving) were 
compared over various factors with PD patients without any ICDs or cravings. 
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RESULTS 
Part One 
 62 PD patients and 23 control subjects were enrolled in the first part of the study 
seeking to identify the determinants of craving in PD (Table 2). PD patients had 
significantly worse olfactory function (t-test: p=0.0001, Fisher’s exact method comparing 
scores of 0 and 3: p=0.019, scores of 0 and 2: p=0.088) and scored significantly higher on 
mood scales (anxiety, p=0.028; OCD, p=0.048). PD patients were more likely to be male 
(p=0.0001).  
 In this part of the study, subjects only completed the CQ if they stated that they 
craved sweets.  33 PD subjects (53%) identified themselves as cravers, with a mean CQ 
of 4.51 (SD 1.3).  Of these, 22 PD subjects (67%) indicated they experienced craving 
before being diagnosed with PD. 9 control subjects (39%) identified themselves as 
cravers, with a mean CQ of 3.92 (SD 1.3). The 75th percentile of CQ scores amongst PD 
cravers was 5.5, with 9 PD subjects (15%) scoring at or higher than this (mean CQ 6.06, 
SD 0.4). These subjects were designated “problem cravers”. By contrast, only 1 control 
craver (4%) scored above this range (CQ = 6.5). CQ scores were predominantly driven by 
strong responses to questions pertaining to expectancy (urges and desires to eat the 
craved sweet food in anticipation of the positive benefits of doing so) and 
purposefulness (urges and desires coupled with intent and planning to eat the craved 
sweet food). 
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 Table 3 compares PD subjects with problem craving (PD cravers) (n=9) with PD 
subjects who were “non-cravers” (n=53) and control subjects. When compared with PD 
non-cravers using t-tests for continuous variables and fisher’s exact method for 
categorical variables, PD cravers were more likely to be female (p=0.0001), have a higher 
H&Y stage (t-test: p=0.0001, fisher’s exact method: insignificant differences between 
scoring groups), have a longer duration of disease (p=0.009), a lower Q-SIT score (t-test: 
p=0.0001; fisher’s exact method: insignificant differences between scoring groups) and 
higher SCl-90-R depression score (p=0.048). There were no significant differences in age, 
smoker status, UPDRS Part 3 score, levodopa equivalent doses, or anxiety and 
obsessive-compulsive SCL-90-R scores. PD subjects with problem craving did report a 
higher food frequency for sweet foods than non-cravers and control subjects, though it 
was only significant when compared with control FFQ scores (p=0.02).  
When comparing PD cravers with control subjects, PD cravers also scored 
significantly lower on Q-SIT (t-test: p=0.001; fisher’s exact method comparing scores of 0 
and 2 (p=0.0179); 0 and 3 (p=0.0182)) and had higher scores on depressive and obsessive-
compulsive subscales (p=0.013 and p=0.013). There was no difference between PD 
cravers and controls in terms of age, gender, smoker status or anxiety.  
When analyzing a patient’s ability to taste sweet, salty, bitter or sour, thresholds 
were extrapolated to a 4-point scale (1= taste threshold at the lowest concentration and 4 
= unable to identify taste, Figure 1). There was no association found between taste 
thresholds and Parkinson’s disease (comparing PD patients and controls), or between 
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taste thresholds and craving in Parkinson’s disease (comparing PD cravers and PD non-
cravers) for any of the four taste types fisher’s exact method. Additionally, there was no 
correlation between CQ scores in PD patients with problem craving and taste threshold 
for any of the four taste types (data not shown).  
 Amongst PD patients stating they craved sweets (n=33), 12 (36%) stated the 
craving was for chocolate foods, 7 stated that they craved cookies (21%), and 6 craved ice 
cream (18%). Pastries, sweet beverages, fruits, and candies were each craved by 2 PD 
subjects (6% each). CQs assessed according to type of sweet food craved did not 
demonstrate any apparent pattern, though cravings for chocolate, ice cream, and sweet 
beverages were the strongest cravings. 
 
Part Two 
 To assess the prevalence of sweet craving in PD and the relationship of PD-
related factors and other ICDs, 128 PD patients and 69 control subjects completed 
questionnaires as previously described. The average age of PD subjects was 63.8 years, 
and the average age of controls was 59.8 years (p=0.008).  Average age at PD onset was 
56 years ( 10.5), and average duration of PD at time of participation was 8 years ( 4.9). 
Mean UPDRS part III score assessed while on medications was 20.2 ( 11.4, n=94) and 
mean levodopa equivalent dose was 798.80 ( 491.3 mg). 80 subjects (63%) were taking a 
dopamine agonist at the time of participation. 
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 We found the prevalence of sweet craving to occur in 5.5% of our sample of 
patients with PD and in 4.3% of controls (non-significant, p=0.36).  Table 4 shows the 
prevalence of ICDs in our cohort of PD patients and controls; except for differences in 
compulsive gambling (p=0.048), there was no significance differences in the prevalence 
of ICDs between PD patients and controls.  
 Figure 2 shows the mean scores on the various questionnaires according to 
disease state and exposure to dopamine agonist medications. PD patients scored 
significantly higher than controls on SOGS (p=0.0006), and trended towards significance 
with higher scores on the CQ (p=0.064). When separating the PD group into those taking 
dopamine agonists (PD+DA) and those not taking a dopamine agonist (PD-DA), the 
PD+DA group scored significantly higher on SOGS (p=0.024), YBOCS-CUV (p=0.046), 
and CQ (p=0.046) than controls. The PD-DA- group’s scores were not significantly 
different from controls on any of the questionnaires (Table 5). 
 Factors that positively correlated with scores on the CQ (Pearson’s correlation 
coefficient, r) included duration of PD (p=0.003), levodopa equivalents (p=0.009), history 
of OCD (p=0.044), and history of depression (p=0.049), while age at onset of PD 
negatively correlated with CQ scores (p=0.015) (Table 6). History of anxiety had a trend 
of significance in its positive correlation with CQ (p=0.086). The correlates of scores on 
the CQ and other ICD scales are shown in Table 6. Age at onset, duration of PD and 
history of OCD were the most common correlates.  
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 The proportions of subjects with at least one compulsive behavior (CB) or 
craving were compared using the z-test for two proportions. 10.1% of controls (n=7) 
were found to have a CB or craving. When compared to the 12.5% (n=16) of all PD 
patients with a CB using a 1-tail confidence level of 95%, the difference was not 
significant (p=0.31). 13.8% (n=11) of PD patients taking a dopamine agonist were found 
to have a CB or craving, also non-significant when compared to controls (p=0.25). Only 
10.4% (n=5) of PD patients not taking a dopamine agonist were found to have a CB. 
When compared to the proportion in controls using a 2-tailed z-test, differences were 
once again not significant (p=0.96). 6 PD patients and one control subject had more than 
one CB.  As a group, PD patients with CBs (including craving for sweets) had a longer 
duration of PD (p=0.031) and younger age at onset (p=0.012), and scored significantly 
higher on all scales than PD patients without CBs (Table 7). 
 Taken together, levodopa equivalent doses and dopamine agonist equivalent 
doses were not significantly different in PD patients with a CB or craving compared to 
those without (Table 8). Of the 16 PD patients with an impulse control disorder or 
craving, seven subjects (1 in monotherapy) were taking pramipexole, three subjects 
(none in monotherapy) were taking ropinirole, 1 subject was taking pergolide (not in 
monotherapy), and two subjects were taking levodopa in monotherapy. The mean 
dopamine agonist equivalent doses in those with a CB or craving separated by type of 
dopamine agonist were also no different. The odds ratio for the presence of any 
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compulsive behavior or craving was 1.07 for pramipexole, 1.06 for ropinirole, and 0.31 
for levodopa. 
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TABLES AND FIGURES 
Table 1:  Concentrations of solutions used for filter discs 
Sweet 10% 25% 60% 
Salty 1.25% 5% 20% 
Sour 0.25% 1% 4% 
Bitter 0.025% 0.1% 0.5% 
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Table 2. Characteristics of PD and control subjects participating in a pilot study of 
sweet craving 
 
 PD patients 
(N = 62) 
Controls 
(N = 23) 
p value 
Mean age 64.4 years 
(±10.7) 
64.4 years 
(±10.3) 
0.98 
Gender 35M (56%) 7M (30%) 0.0001 
Mean PD Duration 
(± SD) 
7.1 years 
(±4.9) 
 
N/A -- 
Mean UPDRS – Pt. 3 (± SD) 
(N = 50) 
26.7 
(±12.2) 
 
N/A -- 
Mean Hoehn & Yahr (± SD) 
(N = 50) 
 
1.9 
(±0.6) 
N/A -- 
Mean FFQ (± SD) 14.8 
(±9.0) 
13 
(±6.2) 
 
0.38 
Mean CQ (± SD) 4.51 
(±1.32) 
(N=33) 
 
3.92 
(±1.30) 
(N=9) 
0.24 
Mean Q-SIT (± SD)* 1.27 
(±0.9) 
2.17 
(±0.7) 
0.0001 
Mean Depression subscale of 
SCL-90-R (± SD) 
 
1.0 
(±0.85) 
0.70 
(±0.58) 
0.12 
Mean Anxiety subscale of 
SCL-90-R (± SD) 
 
0.9 
(±0.77) 
0.50 
(±0.61) 
0.028 
Mean OCD subscale of 
SCL-90-R (± SD) 
1.2 
(±0.85) 
0.80 
(±0.72) 
0.048 
*Using fisher’s exact method, there was a significant association between PD and lower QSIT 
scores when comparing QSIT scores of 0 (no correct answers) and 3 (all correct answers) (p=0.019) 
in PD patients and controls.  
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Table 3. Characteristics of PD patients with problem sweet craving (CQ>5.5) in 
a pilot study 
 
PD cravers 
(N=9) 
PD non-
cravers 
(N=53) 
P value 
Controls 
(N=23) 
P value 
(vs. PD 
cravers) 
Age, yrs 
(SD) 
 
66.3 
(±11.4) 
64.0 
(±10.7) 
0.56 
64.4 
(±10.3) 
0.65 
Gender 
 
3M (33%)  32M (60%) 0.0001 7M (30%) 0.524 
Current/Past Smoker 4 Yes (44%) 21 Yes (40%) 0.41 10 Yes (43%) 0.84 
UPDRS-3 
(SD) 
31.6 
(±11.5) 
N=7 
25.9  
(±12.3)  
N=43 
0.26 N/A -- 
H&Y* 
(SD) 
2.10 
(±0.38) 
N=7 
1.9 
(±0.61) 
N=43 
0.0001 N/A -- 
PD duration 
(SD) 
 
10.9 (±5.90) 
6.42  
(±4.4) 
0.009 N/A -- 
Levodopa 
equivalents, mg (SD) 
 
382  
(±242) 
483 
(±458) 
0.52 N/A -- 
FFQ 
(SD) 
 
19.3 
(± 7.7) 
14.1 
(± 9.1) 
0.11 
13.0 
(±6.2) 
0.02 
Q-SIT** 
(SD) 
 
1.0 
(±1.1) 
1.32 
(±0.89) 
0.0001 
2.17 
(±0.72) 
0.0001 
SCL-90-R Anxiety 
(SD) 
 
1.10 
(± 1.10) 
0.80 
(± 0.71) 
0.29 
0.50 
(± 0.61) 
0.057 
SCl-90-R Depression 
(SD) 
 
1.50 
(±1.15) 
0.90 
(± 0.76) 
0.048 
0.70 
(± 0.58) 
0.013 
SCL-90-R OCD 
(SD) 
 
1.6 
(± 0.88) 
1.10 
(± 0.83) 
0.103 
0.80 
(± 0.72) 
0.013 
*Using fisher’s exact method, no association was found between craving and H&Y scoring. 
**Using fisher’s exact method, there was a significant association between craving in PD and 
lower Q-SIT scores when comparing QSIT scores of 0 and 2 (p=0.0179) and 0 and 3 (p=0.0182) 
between PD cravers and controls. There was no significant association between craving and Q-
SIT scores when comparing scores for PD cravers and PD non-cravers. 
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Table 4: Prevalence of compulsive behaviors 
 PD patients  
(N=128) 
Controls  
(N=69) 
P 
value 
Gambling  3.9% (N=5) 0 0.048 
Shopping  1.6% (N=2) 0 0.148 
Computer use  1.6% (N=2) 1.4% (N=1) 0.475 
Binge eating  3.1% (N=4) 2.9% (N=2) 0.465 
Sexuality  6.3% (N=8) 4.3% (N=3) 0.290 
Sweet craving  5.5% (N=7) 4.3% (N=3) 0.366 
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Table 5. Mean Scores on Various Questionnaires:  
Control vs PD, Control vs PD: DA+, Control vs PD: DA- 
 
 
Control 
N=69 
PD All 
N=128 
p-
value 
PD: DA+ 
N=80 
P-
value 
PD: 
DA- 
N=48 
P-value 
SOGS 
(SD) 
 
0.13 
(0.48) 
0.61 
(1.87) 
0.0006 0.65 
(1.99) 
0.024 0.54 
(1.68) 
0.100 
YBOCS-
SV 
(SD) 
 
1.46 
(2.69) 
1.88 
(3.59) 
0.35 2.03 
(3.72) 
0.28 1.65 
(3.39) 
0.75 
YBOCS-
CUV 
(SD) 
 
2.46 
(3.81) 
3.45 
(4.87) 
0.12 3.95 
(5.26) 
0.046 2.63 
(4.06) 
0.82 
YBOCS- 
BE 
(SD) 
 
2.06 
(4.62) 
2.10 
(4.54) 
0.95 2.16 
(4.91) 
0.90 2.00 
(3.88) 
0.94 
SCS 
(SD) 
 
1.13 
(0.43) 
1.16 
(0.40) 
0.63 1.17 
(0.35) 
0.54 1.15 
(0.47) 
0.81 
CQ 
(SD) 
 
3.07 
(1.26) 
3.42 
(1.28) 
0.064 3.49 
(1.31) 
0.046 3.32 
(1.22) 
0.28 
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Table 6: Factors influencing scores on CB questionnaires in 128 PD patients  
(Pearson’s correlation coefficient, r) 
 
 SOGS YBOCS-
SV 
YBOCS-
CUV 
YBOCS
-BE 
SCS CQ 
Age -0.0770 -0.0705 -0.1565 
p=0.078 
-0.1562 
p=0.078 
 
-0.0818 -0.1014 
Male 
Gender 
-0.0131 -0.0845 0.0517 0.1172 0.2884 
p=0.001 
 
-0.0516 
Duration 
PD 
0.0757 0.2152 
p=0.015 
0.1363 0.0836 0.3282 
p=0.0002 
 
0.2615 
p=0.003 
Age at 
onset of PD 
-0.1002 -0.1601 
p=0.071 
-0.2019 
p=0.022 
-0.1824 
p=0.039 
-0.2308 
p=0.009 
 
-0.2155 
p=0.015 
History of 
depression 
0.0748 0.0597 -0.0339 0.1203 -0.1689 
p=0.057 
 
0.1745 
p=0.049 
History of 
anxiety 
0.2128 
p=0.0159 
0.1917 
p=0.0302 
0.0005 0.1530 
p=0.085 
 
-0.0304 0.1525 
p=0.0857 
History of 
OCD 
0.2475 
p=0.005 
0.2146 
p=0.015 
0.1118 0.1528 
p=0.085 
 
0.2106 
p=0.017 
0.1786 
p=0.044 
Levodopa 
equiv. (mg) 
0.0082 0.2034 
p=0.021 
0.1579 
p=0.075 
 
0.1046 0.0847 0.2300 
p=0.009 
UPDRS 
motor  
(n=94) 
-0.0329 -0.0549 -0.2651 
p=0.002 
0.0580 -0.0890 0.0884 
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Table 7: Characteristics of PD patients with CB 
 At least 1 
CB (n=16)  
No CB 
(n=112)  
p 
value  
PD duration (yrs)  10.1 
(5.82) 
 
7.29 
(4.68) 
0.031 
UPDRS score (n=94) 18.22 
(14.9)    
(n=9) 
20.41 
(11.0)  
(n=85) 
0.59 
Age (yrs)  60.2 
(9)  
 
64.3 
(9.5) 
0.11 
Age at onset PD 50.1 
(9.0) 
 
57.1 
(10.4) 
0.012 
Levodopa equiv. 
(mg)  
955.5 
(618.4) 
779.5 
(481.1) 
0.19 
SOGS  2.88 
(4.24) 
0.29 
(0.86) 
0.028 
YBOCS-SV  5.31 
(6.73) 
1.39 
(2.58) 
0.035 
YBOCS-CUV  8.63 
(7.37) 
2.71 
(3.92) 
0.006 
SCS  1.83 
(0.81) 
1.07 
(0.14) 
0.002 
YBOCS-BE  7.19 
(7.83) 
1.40 
(3.32) 
0.010 
CQ  4.89 
(1.51) 
3.22 
(1.1) 
<0.0001 
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Table 8. Levodopa equivalent doses of PD patients with and without ICD 
 With ICD 
n=16 
No ICD 
n=112 
p 
value 
Total levodopa 
equivalent dosage  
 
955.5+618.4 779.1+481.1 0.19 
DA equivalent dosage  281.9+266.1 190.3+210.1 0.12 
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Figure 1: Taste Thresholds in Controls, PD Non-Cravers and PD Cravers* 
 
 
 
 
 
 
 
 
 
 
 
 
*There was no association found between taste thresholds and Parkinson’s disease (comparing 
PD patients and controls), or between taste thresholds and craving in Parkinson’s disease  
(comparing PD cravers and PD non-cravers) for any of the four taste types using fisher’s exact 
method. 
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Figure 2: Mean Questionnaire Scores for Controls, PD Patients, PD Patients on 
DAs, PD Patients not on DAs 
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DISCUSSION 
This study was developed after the observation that several patients reported a 
craving for sweets after diagnosis and treatment of PD.  Several lines of evidence 
suggest that this is a true phenomenon rather than being an epiphenomenon of aging or 
similar to trends in the general population. Levine et al (2003) studied alcohol-preferring 
rats and found that they consume more of a sucrose solution than non-alcohol preferring 
rats. This is supported by studies demonstrating that increased sucrose/saccharin 
consumption in rats also leads to greater self-administration of drugs of abuse, including 
morphine, cocaine, and amphetamine (DeSousa 2000, Gosnell 1995, Levine 2003) but 
when a glucose or saccharin solution is made available, self-administration of cocaine is 
reduced (Carroll 1989, Levine 2003). Others have found that ingestion of sucrose 
increased dopamine release in the nucleus accumbens, mostly in rats classified as high-
sugar feeders (Hajnal 2001, Sills 1998) and administration of dopamine antagonists 
caused a reduction in the intake of sucrose solutions (Hsiao 1995, Weatherford 1990). 
Past studies have noted that the sweet taste of candies, chocolates and other cravable 
sweets is an indicator to our brain that the food has a high calorie per unit weight ratio 
(Green 2012) and these highly caloric foods tend to activate reward pathways in the 
brain (Fortuna 2010). Together, these studies suggest that there is a relationship between 
the intake of sweet substances and drugs of abuse, as well as dopamine mediated 
reward systems. 
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In a study of food craving in a general population sample, the target for craving 
was chocolate in 49% of subjects compared to baked goods in 11%, “something sweet” in 
16%, and savory foods in 12% (Bruinsma and Taren, 1999).  Wolz et al (2009) have since 
reported that chocolate consumption, though not sweet consumption in general, was 
significantly higher in a group of 274 PD patients compared to 234 household controls.  
The authors also found that PD patients were more likely to be older, male, and have 
depression. 
In a functional MRI study of subjects reporting chocolate craving, Rolls and 
McCabe (2007) found activation of the mid and medial parts of the orbitofrontal cortex 
and ventral striatum, with a varied time response depending on whether a visual or 
actual taste stimulus was provided. Interestingly, similar areas of the brain are activated 
in PD patients suffering from pathologic gambling (Frosini 2010). This connection can be 
seen again in the effects of opioid receptor antagonists, like nalmefene and naltrexone, 
which bind to opioid receptors and block the body from responding to opiates and 
endorphins. This can have many effects, one of which is dampening the reported 
pleasantness of palatable foods (including sweets) in normal subjects (Kelley 2002, 
Yeomans and Wright 1991), and alleviating pathologic gambling in both non-PD 
subjects (Grant et al, 2006) and PD patients (Bosco 2012). Bosco et al found that 
treatment with naltrexone resulted in remission of pathological gambling in 3 PD 
patients when discontinuation of DAs and treatment with serotonin reuptake inhibitors 
did not improve the ICD. Together these studies support the notion that sweet cravings 
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in PD have a neuro-biologic basis, may share common pathophysiologic underpinnings 
with other disorders of impulse control, and may be related to dopamine-mediated 
reward systems.  
In Part One of our study, we found that PD patients felt more anxious and 
reported more OCD symptoms than controls. They were also more likely to be male and 
have greater olfactory deficit. These findings are consistent with known population 
characteristics of PD. By contrast, we found that PD cravers, when compared with PD 
non-cravers, were more likely to be female, have more severe H&Y staging and have a 
longer disease duration (Table 3). PD cravers had significantly greater olfactory 
dysfunction and were more depressed than PD non-cravers, indicating that severity of 
olfactory loss and depressive symptoms amongst all PD patients are relevant to the 
presence of sweet craving. Levodopa equivalents were not different between PD cravers 
and PD non-cravers. In summary, we found that the determinants of craving in 
Parkinson’s disease are female gender, longer disease duration and greater PD severity, 
more advanced olfactory dysfunction and greater symptoms of depression. Thus, there 
were no relevant non-disease related factors that were associated with sweet craving, 
e.g., smoking, nasal surgery, taste perception, etc. This suggests that craving sweets in 
PD is intrinsic to the disease process and not simply related to general population 
trends.  
The objects of sweet cravings in our cohort of patients were chocolate, cookies, 
ice cream, pastries, candies, fruits and sweet beverages. These foods are also the focus of 
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sweet craving in the general population, which tells us that the object of craving doesn’t 
necessarily change in PD.  
In Part 2 of this study, scores on CQ, regardless of if a patient reported cravings 
or not, significantly correlated with duration of PD (positive), age at onset of PD 
(negative), history of OCD (positive), history of depression (positive) and total levodopa 
equivalents (positive), with trends to significance for correlation with history of anxiety 
(positive) (Table 6). Age at onset of PD was not examined in Part 1, but was assessed in 
Part 2 as a known factor associated with development of ICDs, and was found to 
significantly and negatively correlate with scores on CQ, similar to other CBs. When 
analyzed according to DA exposure, CQ scores were highest amongst PD patients 
exposed to a DA, followed by those unexposed to a DA, and finally control subjects 
(Table 5). As a group, PD patients scored significantly higher on the SOGS than controls. 
Similarly to craving sweets, this was determined mostly by dopamine agonist exposure, 
as the relationship was not significant in DA unexposed patients. These findings support 
our original conclusions from Part 1 that craving for sweets is a disease-related 
phenomenon and additionally, is possibly related to medications used to treat PD. 
Furthering this notion is the positive correlation between total levodopa 
equivalents, which included calculations of dopamine agonist equivalent doses, and CQ 
scores (Table 6). This correlation can be attributed to the probable combination of both 
levodopa and dopamine agonists in a significant proportion of these patients.  Indeed, 
the DOMINION study found that a combination of both therapies could increase the 
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likelihood of ICD development by nearly 50%. The DOMINION study also linked both 
DA and L-dopa treatments independently of one another to an increased likelihood of 
ICDs, but found that the DA association to ICDs was higher than the L-dopa association. 
Interestingly, the only other ICD that held a significant correlation with levodopa 
equivalent dosing in our cohort of PD patients was compulsive shopping. The reasons 
for this selectivity are unclear, but may pertain to sample size. 
PD patients with at least one ICD (including craving for sweets) also had 
younger age at PD onset and longer PD duration (Table 7). We saw this relationship in 
part 1 of the study, and it also seems to be a consistent finding across ICD studies in PD 
(Kim 2012, Voon 2007, Leeman 2011). A possible explanation for this phenomenon may 
be that physicians often treat younger patients with DAs first and often at higher dosing 
to avoid and/or delay the motor complications of L-dopa treatment (Bastiaens 2013, 
Rana 2013). 
Patients with ICDs were taking more PD medications including DAs, but this 
was not statistically significant, possibly due to sample size. The risk of developing an 
ICD on dopamine agonists was higher than with levodopa, as found in the DOMINON 
study. There was no difference in risk of ICD development between pramipexole and 
ropinirole, confirming it is a drug class effect, and excluding the possibility that the 
nature of the drug exposure determines the presence of an ICD. 
In general, PD patients with at least one ICD including craving (regardless of 
type) scored significantly higher on all ICD scales (including craving). This suggests that 
41 
 
general trends to greater compulsivity exist amongst PD patients diagnosed with an 
ICD, but the reasons for manifestation as one CB over another are not clear. It also 
suggests that if one ICD is present, patients should be screened for and counseled about 
the presence of others, including craving for sweets.  
Our correlation analysis (Table 6) across CBs demonstrated that factors that 
influence how PD patients answer questions about sweet craving are the same as factors 
that would influence how they answer questions about other compulsive behaviors, 
indicating that craving for sweets has the same demographic and disease-related 
determinants as other ICDs. Specifically, the phenomenon of craving for sweets in PD 
should be considered in the same category as other disorders of impulse control, and has 
features of a compulsive behavior.   
 In summary, this report finds that craving for sweets is a disease-related 
phenomenon in PD. It is most likely to occur in patients who are female with younger 
age of onset, longer duration of disease, a history of depression and/or OCD, and a 
higher Hoehn & Yahr staging.  It may take the form of craving for chocolate, cookies, ice 
cream, candies or sweet beverages. DA exposure appears to play a significant role, and 
other disorders of impulse may also be present in individuals who crave sweets. As a 
phenomenon, sweet craving closely resembles ICDs in PD based on our findings. 
Notably, in the largest cross-sectional study conducted to date (Weintraub 2010), all 
factors for sweet craving in the present study are also reported as relevant factors for 
other ICDs.  
42 
 
We therefore suggest that the spectrum of ICDs in PD be expanded to include 
craving for sweets. Patients should be counseled about the spectrum of ICDs upon 
diagnosis and then continuously assessed for any developments throughout the course 
of PD therapy. Clinicians should evaluate their patient for any risk factors that have 
been associated with ICDs in PD and discuss these factors and different treatment 
options with their patient (Leeman 2011). This initial analysis may serve as a way of 
preventing the development of an ICD in an at-risk individual (Leeman 2011), or even 
minimizing the consequences of sub-threshold symptoms if already present. This first 
step is important because once an ICD has developed, it can be difficult to manage (Vilas 
2012). The most effective treatment is to decrease or discontinue DA therapy (Bastiaens 
2013, Leeman 2011, Nirenberg and Waters 2006). Nirenberg and Waters (2006) reported 
that in addition to other ICDs, craving for sweets improved after DA reduction.  Some 
patients, however, may not tolerate this process due to development of dopamine 
agonist withdrawal syndrome, which may include panic attacks, anxiety, orthostatic 
hypotension, diaphoresis, fatigue, dysphoria, pain, and drug cravings (Bastiaens 2013, 
Vilas 2012).  While DA dose reduction is certainly a reasonable strategy to consider if 
problematic sweet cravings occur, prospective studies are needed to verify the 
emergence of craving for sweets after PD diagnosis, relationship to PD treatment, and 
response to interventions.   
 Our study is limited by a number of weaknesses.  One major weakness is the 
small sample size in Part 1. With only nine problem cravers with Parkinson’s disease in 
43 
 
the first part of our study, we were forced to use the less accurate t-test to analyze our 
continuous data, which meant that even when our p-values showed significance, they 
were less impactful than a z-test. When using fisher’s exact method for H&Y and QSIT 
scores, these low numbers also made it more difficult to find significance between 
groups. Our cut-off of the 75th percentile on the CQ in patients who self-identified as 
cravers may have artificially elevated the threshold for diagnosis of sweet craving, and 
we therefore may have under-reported the true prevalence of craving for sweets in PD 
in the 2nd part of the study. Indeed, 53% of patients in part 1 identified themselves as 
cravers, although a smaller percentage were designated “problem cravers”. This holds 
true of established ICDs as well, in which “sub-threshold” abnormal behaviors may exist 
but do not meet criteria for an ICD diagnosis. Our subjective clinical experience suggests 
that more than 5.5% of the PD population experiences craving for sweets, and it may in 
fact be more common than other ICDs.  Similarly, the reported prevalence rates of 
various ICDs in our study (Table 4) differ from those in the published literature. The 
lack of standardized and comprehensive neuropsychological measures and the reliance 
on historical and self-reported symptomatology (rather than concurrently measured 
neuropsychiatric symptoms), likely account for a major proportion of this discrepancy. 
At the time this study was implemented, the self-administered Questionnaire for 
Impulsive-Compulsive Disorders in Parkinson’s Disease (QUIP) (Weintraub 2009) had 
not been validated. Finally, we have drawn inferences regarding the biologic 
underpinnings of craving for sweets in PD from several lines of evidence in the basic 
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and clinical scientific literature, but did not measure these directly in our patients (e.g., 
functional MRI, measurement of how highly caloric foods activate reward pathways in 
the brain, etc).  
For the most part, however, our data was distributed with similar standard 
deviations, allowing us to assume equal variances, which lent to more accurate results. 
Furthermore, in the second part of our study, we had use of larger sample sizes, 
allowing us to use z-tests in many cases. Another major strength in our study is that it 
offers information on a subject that has been, for the most part, ignored in the previous 
literature but may have relevance to our understanding of PD and disorders of impulse 
control.  Several significant associations were found, and are replicated in the context of 
other known ICDs within our own study. Our findings regarding sweet cravings in the 
PD population should be reproduced in a larger study.  
The overlying goal of this study was to not only establish sweet craving as a 
compulsive behavior in PD, but also to expand our knowledge on impulse controls 
disorders in general. By increasing our awareness of this complication and by reaching a 
greater understanding of what variables make impulse control disorders more likely to 
develop, we can improve the quality of care that clinicians can provide for their patients. 
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